When I last wrote about the makers of Byetta and Januvia, two leading diabetes drugs, I called them the Hatfields and McCoys of diabetes care. Good call, that one. The two manufacturers, Amylin ...

(Reuters) - Merck and Co's diabetes drug Januvia achieved the main goal of a long-awaited heart safety study, according to preliminary results released by the drugmaker on Monday, likely removing a ...

(Reuters) - Details of a large heart safety study presented on Monday appear to give Merck and Co's diabetes drug Januvia a clean bill of health, possibly setting the stage for a return to sales ...

Merck (MRK 1.70%) stock has become dependent on its diabetes drug Januvia over the past couple of years for revenue growth. The franchise made up 12% of Merck's sales in the first quarter and probably ...